MAP2K7 and melanoma: We also found an increased miR-378a-5p expression in the A375 melanoma cells resistant to Vemurafenib (BRAF inhibitor) or to Dabrafenib/Trametinib (BRAF/MEK inhibitors)22 compared to sensitive ones (Fig. 1d).